# Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

> **NCT05577000** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Martin, MD** · enrollment: 5 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Manufactured Anti-BCMA CAR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05577000
- **Lead sponsor:** Thomas Martin, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-18
- **Primary completion:** 2025-11-30
- **Final completion:** 2038-08-31
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577000, "Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05577000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*